Intercept Pharmaceuticals Inc (ICPT) : National Planning Corp scooped up 625 additional shares in Intercept Pharmaceuticals Inc during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 26,205 shares of Intercept Pharmaceuticals Inc which is valued at $3.1 Million.Intercept Pharmaceuticals Inc makes up approximately 0.24% of National Planning Corp’s portfolio.
Other Hedge Funds, Including , Parallax Volatility Advisers added ICPT to its portfolio by purchasing 471 company shares during the Fourth Quarter which is valued at $56,586.Blackrock Fund Advisors reduced its stake in ICPT by selling 52,194 shares or 10.69% during the fourth quarter. The Hedge Fund company now holds 435,983 shares of ICPT which is valued at $52.4 Million. Intercept Pharmaceuticals Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Vanguard Group Inc boosted its stake in ICPT during the Q4 period, The investment management firm added 38,092 additional shares and now holds a total of 1,089,655 shares of Intercept Pharmaceuticals Inc which is valued at $130.9 Million. Intercept Pharmaceuticals Inc makes up approx 0.01% of Vanguard Group Inc’s portfolio.Cam Group Holding As boosted its stake in ICPT during the Q4 period, The investment management firm added 440 additional shares and now holds a total of 3,800 shares of Intercept Pharmaceuticals Inc which is valued at $456,532. Intercept Pharmaceuticals Inc makes up approx 0.01% of Cam Group Holding As’s portfolio. Numeric Investors sold out all of its stake in ICPT during the fourth quarter. The investment firm sold 3,300 shares of ICPT which is valued $386,925.
On the company’s financial health, Intercept Pharmaceuticals Inc reported $-3.62 EPS for the quarter, missing the analyst consensus estimate by $ -0.55 based on the information available during the earnings call on Feb 23, 2016. Analyst had a consensus of $-3.07. The company had revenue of $.45 million for the quarter, compared to analysts expectations of $.43 million. The company’s revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.63 EPS.
Many Wall Street Analysts have commented on Intercept Pharmaceuticals Inc. Intercept Pharmaceuticals Inc was Upgraded by Wells Fargo to ” Outperform” on Apr 5, 2016. Intercept Pharmaceuticals Inc was Initiated by Goldman to “Neutral” on Mar 30, 2016. Credit Suisse Initiated Intercept Pharmaceuticals Inc on Mar 30, 2016 to “Outperform”, Price Target of the shares are set at $200.
Intercept Pharmaceuticals Inc opened for trading at $131.76 and hit $140.4085 on the upside on Monday, eventually ending the session at $133.55, with a gain of 2.13% or 2.79 points. The heightened volatility saw the trading volume jump to 12,89,406 shares. Company has a market cap of $3,259 M.
Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.